Atlas Trials

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients

Clinical trial NCT05046665 · COMPLETED

Trial details

NCT number
NCT05046665
Sponsor
South Metropolitan Health Service
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Urothelial Carcinoma
Start date
2021-05-14
Primary completion
2022-08-09
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.